BioNTech (BNTX) Stock Forecast & Price Target

$98.52 -0.74 (-0.75%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$99.04 +0.52 (+0.53%)

As of 09/25/2026 07:45 PM Eastern

Compare

BioNTech - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 19 Analyst Ratings

Sell
1

Hold
5

Buy
13

Based on 19 Wall Street analysts who have issued ratings for BioNTech in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 19 analysts, 1 has given a sell rating, 5 have given a hold rating, 12 have given a buy rating, and 1 has given a strong buy rating for BNTX.

Consensus Price Target

$126.00
27.89% Upside

According to the 19 analysts' twelve-month price targets for BioNTech, the average price target is $126.00. The highest price target for BNTX is $155.00, while the lowest price target for BNTX is $94.00. The average price target represents a forecasted upside of 27.89% from the current price of $98.52.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for BNTX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for BioNTech and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BNTX Analyst Ratings Over Time

Type	Current Forecast 9/26/25 to 9/26/26	1 Month Ago 8/27/25 to 8/27/26	3 Months Ago 6/28/25 to 6/28/26	1 Year Ago 9/26/24 to 9/26/25
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	12 Buy rating(s)	13 Buy rating(s)	13 Buy rating(s)	11 Buy rating(s)
Hold	5 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)	3 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$126.00	$127.81	$129.56	$134.56
Forecasted Upside	27.89% Upside	14.73% Upside	42.03% Upside	37.20% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

BNTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BNTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

BioNTech Stock vs. The Competition

Type	BioNTech	Healthcare Companies	Broader Market
Consensus Rating Score	2.68	2.31	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	27.89% Upside	764.29% Upside	19.21% Upside
News Sentiment Rating	Neutral News See Recent BNTX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
9/16/2026	UBS Group 4 of 5 stars	David Dai Not Rated	Reiterated Rating	Buy
9/16/2026	Berenberg Bank 2 of 5 stars		Set Target		$140.00	+44.79%
9/8/2026	BMO Capital Markets 3 of 5 stars	Evan David Seigerman 3 of 5 stars	Downgrade	Outperform ➝ Market Perform	$128.00 ➝ $105.00	+1.20%
8/31/2026	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	John Newman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$142.00 ➝ $136.00	+33.24%
8/5/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Geoff Meacham Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$130.00 ➝ $125.00	+36.11%
7/8/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Terence Flynn Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$126.00 ➝ $119.00	+26.79%
7/6/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Sell (D-)
6/5/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jeffrey Walch Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Market Perform
6/1/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Akash Tewari Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy
5/6/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mohit Bansal Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$150.00 ➝ $140.00	+50.09%
Get the Latest News and Ratings for BNTX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for BioNTech and its competitors with MarketBeat's FREE daily newsletter.
4/27/2026	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Robert Burns Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$130.00	+23.27%
3/25/2026	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Asthika Goonewardene Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Strong-Buy
3/17/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy
3/11/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Yaron Werber Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Hold	$116.00 ➝ $94.00	+4.49%
3/11/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Asad Haider Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy
3/10/2026	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform
3/10/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy	$128.00	+53.10%
2/2/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform	$113.00	-0.66%
10/23/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jessica Fye Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Neutral	$121.00 ➝ $120.00	+14.72%
11/19/2024	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Cory Kasimov Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	In-Line ➝ Outperform	$110.00 ➝ $125.00	+22.71%
10/7/2024	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Buy	$97.00 ➝ $136.00	+10.88%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 03:40 PM ET.

Should I Buy BioNTech Stock? BNTX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, September 23, 2026. Please send any questions or comments about these BioNTech pros and cons to contact@marketbeat.com.

BioNTech
Bull Case

Here are some ways that investors could benefit from investing in BioNTech SE:

BioNTech SE is currently trading at $98.46, which is significantly below the consensus price target of $126.00, suggesting substantial potential upside for investors who believe the market is undervaluing the company's long-term growth prospects.
The company maintains a very strong balance sheet with a current ratio of 7.85 and a debt-to-equity ratio of only 0.01, indicating it has ample liquidity and minimal leverage to fund its extensive clinical trials and operations without significant financial risk.
Wall Street analysts maintain a consensus rating of "Moderate Buy" for the stock, with 13 out of 19 analysts issuing Buy or Strong Buy ratings, reflecting a general institutional confidence in the company's strategic direction and pipeline potential.
BioNTech SE is developing a diverse portfolio of cancer immunotherapies, including BNT111 for advanced melanoma and BNT113 for HPV 16+ head and neck cancers, which positions the company to benefit from the growing demand for personalized cancer treatments.
Recent positive sentiment in the mRNA sector, driven by competitors' successes in melanoma treatments, has helped support BioNTech SE's stock price, indicating that investors are increasingly recognizing the broader potential of the company's technology platform beyond infectious diseases.

BioNTech
Bear Case

Investors should be bearish about investing in BioNTech SE for these reasons:

The company reported a loss of $2.53 per share in its most recent quarter, missing analyst estimates, and revenue fell 59.5% year-over-year to $122.31 million, highlighting significant challenges in generating consistent profitability and top-line growth.
CEO Ugur Sahin has been actively selling shares, including a recent sale of 33,000 shares on September 21st and 46,000 shares on September 22nd, which may signal a lack of confidence in the stock's near-term performance or a desire to diversify personal holdings.
BMO Capital Markets recently downgraded BioNTech SE from "Outperform" to "Market Perform" and lowered its price target to $105.00, citing a reduction in 2027 guidance and a clinical setback, which raises concerns about the company's execution capabilities and pipeline risks.
The stock has a beta of 1.29, indicating it is more volatile than the overall market, and it recently hit a 52-week low of $79.52, suggesting that investors may face significant price swings and downside risk in the near term.
BioNTech SE has a negative net margin of 63.54% and a negative return on equity of 6.86%, indicating that the company is currently losing money on every dollar of revenue and is not generating positive returns for shareholders, which is a major concern for value-oriented investors.

BNTX Forecast - Frequently Asked Questions

According to the research reports of 19 Wall Street equities research analysts, the average twelve-month stock price forecast for BioNTech is $126.00, with a high forecast of $155.00 and a low forecast of $94.00.

19 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioNTech in the last year. There is currently 1 sell rating, 5 hold ratings, 12 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BNTX shares.

According to analysts, BioNTech's stock has a predicted upside of 27.89% based on their 12-month stock forecasts.

Over the previous 90 days, BioNTech's stock had 1 downgrade by analysts.

BioNTech has been rated by research analysts at Berenberg Bank, BMO Capital Markets, Canaccord Genuity Group, Citigroup, Morgan Stanley, UBS Group, and Weiss Ratings in the past 90 days.

Analysts like BioNTech more than other "healthcare" companies. The consensus rating for BioNTech is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how BNTX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With BioNTech Recommendations

MarketBeat monitors more than a dozen sources for BioNTech analyst ratings, with the most recent rating issued on 9/16/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioNTech (BNTX) Stock Forecast & Price Target

BioNTech - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

BNTX Analyst Ratings Over Time

BNTX Analyst Recommendations By Month

BNTX Price Targets by Month

BioNTech Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy BioNTech Stock? BNTX Pros and Cons Explained

BioNTech
Bull Case

BioNTech
Bear Case

BNTX Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With BioNTech Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioNTech (BNTX) Stock Forecast & Price Target

BioNTech - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

BNTX Analyst Ratings Over Time

BNTX Analyst Recommendations By Month

BNTX Price Targets by Month

BioNTech Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy BioNTech Stock? BNTX Pros and Cons Explained

BioNTech Bull Case

BioNTech Bear Case

BNTX Forecast - Frequently Asked Questions

What is BioNTech's forecast for 2026?

Should I buy or sell BioNTech stock right now?

Does BioNTech's stock price have much upside?

Has BioNTech been downgraded by Wall Street analysts recently?

What analysts cover BioNTech?

Do Wall Street analysts like BioNTech more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With BioNTech Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

BioNTech
Bull Case

BioNTech
Bear Case